Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Omar Mahmud

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6514-1646; OpenAlex author ID A5065823336, A5137226774. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2024: 3 papers · 2025: 5 papers · 2026: 4 papers

Papers 12

  1. Clinical and molecular features of resected early onset pancreatic ductal adenocarcinoma: insights from the NCDB and cBioPortal. First author DOI 10.1016/j.hpb.2025.12.026↗
  2. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  3. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660↗
  4. Current challenges in screening for pancreatic ductal adenocarcinoma: an appraisal of the METAPAC study Co-author DOI 10.21037/tgh-2026-0049↗
  5. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2025.102969↗
  6. Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A prevalence meta-analysis. Co-author DOI 10.1016/j.ejso.2025.109742↗
  7. Reply to: Comment on "Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A preva… Co-author DOI 10.1016/j.ejso.2025.110111↗
  8. Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis. Co-author DOI 10.1093/jnci/djae294↗
  9. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  10. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  11. Predictors for Long-Term Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. First author DOI 10.1245/s10434-024-15281-1↗
  12. ASO Author Reflections: The Role of Established Prognostic Factors in Long-Term Survival After Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15391-w↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ammar A. Javed · 12 shared papers, 2024–2026 · strength 3.05
  2. Marc G. Besselink · 8 shared papers, 2024–2026 · strength 1.65
  3. Christopher Lee Wolfgang · 7 shared papers, 2024–2026 · strength 1.50
  4. Mahip Grewal · 5 shared papers, 2024–2025 · strength 1.30
  5. Ingmar Florin Rompen · 6 shared papers, 2024–2026 · strength 1.25
  6. Lois A. Daamen · 6 shared papers, 2024–2026 · strength 1.19
  7. Greg D. Sacks · 4 shared papers, 2025–2026 · strength 1.06
  8. Nabiha Akhlaq Mughal · 5 shared papers, 2024–2026 · strength 1.03
  9. Izaak Quintus Molenaar · 5 shared papers, 2024–2026 · strength 0.95
  10. Joseph R. Habib · 5 shared papers, 2024–2026 · strength 0.95
  11. Jin Peng He · 4 shared papers, 2025–2026 · strength 0.82
  12. Daniel Brock Hewitt · 3 shared papers, 2025–2026 · strength 0.73
  13. Christopher L. Wolfgang · 3 shared papers, 2024–2025 · strength 0.72
  14. Thijs J. Schouten · 4 shared papers, 2024–2026 · strength 0.72
  15. Bas Groot Koerkamp · 4 shared papers, 2024–2026 · strength 0.72
  16. Thomas F. Stoop · 4 shared papers, 2024–2026 · strength 0.72
  17. Iris W.J.M. van Goor · 4 shared papers, 2024–2026 · strength 0.72
  18. Paul C. M. Andel · 4 shared papers, 2024–2026 · strength 0.72
  19. Hjalmar C. van Santvoort · 4 shared papers, 2024–2026 · strength 0.72
  20. Freek D. Daams · 3 shared papers, 2024–2026 · strength 0.48
  21. Gijs A. Patijn · 3 shared papers, 2024–2026 · strength 0.48
  22. Maarten W. Nijkamp · 3 shared papers, 2024–2026 · strength 0.48
  23. Kelly J. Lafaro · 3 shared papers, 2024–2026 · strength 0.48
  24. Sebastiaan Festen · 3 shared papers, 2024–2026 · strength 0.48
  25. Richard Andrew Burkhart · 3 shared papers, 2024–2026 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.